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adult age. The latter effect was apparent in post-mortem immuno-
histochemical analyses of the cell proliferation marker BrdU and the
microtubule-associated protein DCX, a marker of newborn neuronal
cells. Chronic CLZ treatment significantly improved the prenatal
PolyI:C-induced working memory deficits, whist at the same time,
it negatively affected working memory performance in adult
offspring born to control mothers. These bidirectional cognitive
effects of clozapine were not paralleled by concomitant effects on
adult hippocampal neurogenesis.
Discussion: Our findings do not support the hypothesis that the
atypical antipsychotic drug clozapine may influence cognitive func-
tions by acting on adult neurogenesis in the hippocampus, regardless
of whether the drug is administered to subjects with or without a
neurodevelopmental predisposition to adult neuropathology.
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Background: Evidence suggests that the pathogenesis of schizo-
phrenia cognitive symptom may involve abnormalities in glutama-
tergic transmission. Particularly, non-competitive antagonists of N-
methyl-D-aspartate (NMDA) receptors such as phencyclidine and
MK801 are known to cause cognitive states resembling schizo-
phrenia in healthy humans and exacerbate preexisting symptoms in
the patients. In rats, the administration of MK801 alters neuronal
activity in the prefrontal cortex (PFC) as well as impairs executive
cognitive function. In this study, we tested the effect of MK801 on
synaptic responses of the cognitively important, hippocampus-PFC
pathway and on executive cognitive function in rats.
Methods: Male Sprague-Dawley rats (350-400 g) were anesthe-
tized by urethane (1.5 g/kg, i.p.) and placed in a stereotaxic frame
(body temperature maintained at 37±0.1 °C). A recording elec-
trode was placed in the mid layer of the prelimbic area (rat PFC),
and a stimulating electrode in ventral hippocampus. The electrode
positions were adjusted to obtain the maximum amplitude of
postsynaptic potential, whose peak appears with an 18.0-20.0 ms
delay after stimulus artifact. The intensity of stimulation was set to
evoke 60% of the maximum response (300-500 μA). The protocol
for behavioral analysis followed Birrell and Brown (J Neurosci, 20,
p4320, 2001).
Results: Single injection ofMK801 (0.1 mg/kg i.p.) induced a gradual
potentiation of the evoked responses which reached a significant
level 2 hours after injection (63±10 at 2 hours, n=12) compared
with saline control (11±6.6%, n=10, p<0.0005). This MK801-
induced potentiation does not require tetanic stimulation unlike the
standard forms of long-term potentiation (LTP). Furthermore,
significant MK801-induced LTP was induced even when single test
stimuli (at 0.033 Hz) were stopped for 1 hour from the time of
MK801 injection (32±2.8% at 2 hours, n=5, p<0.001 compared
with saline control, 0.7±2.2%, n=7), suggesting that the MK801-
induced LTP occurs in the manner independent of synchronized
synaptic stimuli. However, MK801-induced LTP appears to share the
common mechanisms with the standard LTP, since a prior induction
of LTP by tetani (50 pulses at 250 Hz, repeated 10 times at 0.1 Hz;
such a trainwas applied twicewith 6 min interval) severely occluded
a subsequent MK801-induced LTP (19±7.5, n=7, p<0.005).
MK801-induced LTP was blocked also by prior injection of MAP
kinase inhibitor SL-327 (10 mg/kg, i.p., 19.2±9.1%, n=5, p<0.01)
and of mGluR2/3 agonist LY379268 (3 mg/kg, i.p.; 0.2±2.0%, n=5,
p<0.005). Behavioral data showed that the injection of MK801
impairs PFC-dependent extra-dimensional set shifting (p<0.05). In
another series of experiments, we tested the effect of repeated
injections of MK801 (7 or 14 daily injections) on a subsequent
induction of LTP by tetani. We had verified that tetani delivered 24 h
after single MK801 can induce clear LTP (85±17%, n=5). But tetani
delivered 24 hours after a 7th daily injection of MK801 induced LTP
only in 3 out of 6 animals, and tetani 24 hours after a 14th injection
resulted in no LTP (-11±4.1%, n=7, p<0.001). LTP was still absent
72 hours after the 14th daily injection (-3.1±6.4%, n=4, p<0.001).
Rats injected with the 14-daily MK801 showed severe impairments
in the attentional set shifting task.
Discussion: These results suggest that MK801 induces an aberrant
form of LTP in the hippocampus-PFC pathway. When injection is
repeated, MK801 blocks a subsequent LTP induced by tetanic
stimuli. We are currently testing the role of PFC dopamine receptors
for the MK801-induced LTP.
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Background: The importance of cognitive impairment for functional
outcome in patients with schizophrenia has led to the development of
cognitive remediation programs designed to improve cognition. These
interventions have targeted a wide range of cognitive functions.
However, there arenodirect comparisons between treatmentprograms
addressing cognitive functions on different levels of complexity in a
rehabilitation setting. The purpose of this studywas to assesswhether a
planning and problem solving training is more effective in improving
functional capacity in patients with schizophrenia than a traditional
training program addressing basic cognitive functions.
Methods: Eighty-nine patients with schizophrenia or schizoaffec-
tive disorder were randomly assigned either to a training of
planning and problem solving or a training of basic cognition. The
dependent variables included functional capacity as a proxy
measure for functional outcome, problem solving and planning
ability. Assessment of the primary outcome was blind to group
allocation. Participants received computer-assisted cognitive train-
ing three times a week over a three week period.
Results: Amain effect of time indicated that both groups improved in
functional capacity during the study. Calculation of the reliable change
index suggests that this improvement is clinically significant. Contrary
to our main hypothesis, no significant time x group interaction was
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found for functional capacity suggesting that both types of training can
improve functional capacity similarly. Measures of planning and
problem-solving showed a similar pattern with an advantage for
planning and problem solving training on one measure.
Discussion: Our results are in line with previous studies reporting
an improvement of functional capacity when cognitive remediation
is combined with other rehabilitation methods. However, a
differential effect of targeting different cognitive functions on
functional capacity remains to be established.
doi:10.1016/j.schres.2010.02.711
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Background: The NIMH MATRICS Project and related efforts have
stimulated the initiation of several studies of treatments for cognitive
impairment in schizophrenia. Cognitive remediation may provide an
excellent platform for the provision of new learning opportunities and
the acquisition of new skills for patients who are engaged in
pharmacologic trials to improve cognition. However, it is not clear
whether cognitive remediation intervention would be feasible for
large trials involving sites without specific cognitive remediation
expertise. We sought to address the feasibility of a multi-site trial of
cognitive remediation in schizophrenia, called the Cognitive Remedia-
tion in the Schizophrenia Trials Network (CRSTN) study.
Methods: Nine sites from the Schizophrenia Trials Network, formerly
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
schizophrenia trial,were involved in the study. Each sitewas expected to
enroll six patientswith chronicDSM-IV schizophrenia over the course of
approximately3 months, estimating a reasonable rate of recruitment for
a large-scale efficacy trial. Raters were certified on the MATRICS
Consensus Cognitive Battery (MCCB) as the primary outcomemeasure,
the 2nd edition of the UCSD Performance-based Skills Assessment
(UPSA-2) as a co-primary measure, and key secondary measures
including the Cognitive Assessment Interview (CAI) and trained on the
Positive and Negative Syndrome Scale (PANSS). Patients met the
following criteria: age 18-55; not fully satisfied with current level of
functioning and able to identify functional goals; no hospitalization in
last 8 weeks; no change in medication regimen in last 4 weeks; PANSS
delusion and hallucination item scores ≤5, conceptual disorganization
item score≤4, and CalgaryDepression Scale total score≤10;WTAR>5.
Patients were randomized to one of two treatment conditions: 1. the
PositScience Brain Fitness auditory training program with weekly
'bridging groups' adapted from the Neuropsychological Educational
Approach to Remediation (NEAR), that help patients to learn how
cognitive improvement can be applied to functional benefit in everyday
life; or 2. a control condition that involved computer games andweekly
healthy lifestyles groups. Patients were expected to complete the one-
hour auditory training intervention or computer game activities 3-5
times per week until study end, which was 40 sessions or 12 weeks,
whichever came first. Efficacy with theMCCB and UPSA-2was assessed
after 20 sessions and study end. The key indicator to evaluate the
feasibilityof this studywas rateof enrollment, retention, andcompletion
rate of primary outcome measures.
Results: Within the 3-month enrollment period, 67 patients signed
consent, 60 patients were screened, and 53 were enrolled, one short
of the maximum allowed. As of the date of abstract submission, 3
patients (1 receiving cognitive remediation) had terminated the
study, and 32 patients had completed the trial. Of these, 26
completed the maximum 40 sessions and the other 6 patients
completed an average of 30 sessions in 12 weeks.Weekly attendance
in the bridging groupswas excellent. Efficacy datawill be available at
the time of this presentation.
Discussion: In terms of training, enrollment and study completion,
multi-site trials of cognitive remediation using the PositScience
auditory training program with the NEAR method of weekly
bridging groups appear to be feasible, supporting large-scale
efficacy trials of cognitive remediation and the use of cognitive
remediation as a potential platform for large-scale drug trials.
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Background: Cognitive behavioural therapy (CBT) is an important
treatment in conjunction with psychopharmacotherapy in schizo-
phrenia. However, there is only very little research on the effects of
such interventions on brain function. Recent studies have suggested
that jumping to conclusions and a specific attributional style is a
predominant cognitive style in patients which might lead to the
development of delusions.
Methods: In this multi-centre fMRI trial, we investigated the effect
of CBT on neural correlates of "jumping to conclusions" and the
"attributional style" in patients with schizophrenia. Eighty patients
and 80 control subjects were recruited in six centres and measured
with 3-Tesla functional magnetic imaging (fMRI) before and after
9 months of cognitive behavioural therapy.
Results: It could be shown that CBT ameliorates differences in brain
activations between patients and controls after nine months.
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